Adding Obinutuzumab to Bendamustine Clinically Beneficial for Patients With Rituximab-refractory NHL

Share this content:
Obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival.
Obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival.

Obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival, compared with bendamustine monotherapy, in rituximab-refractory patients with indolent non-Hodgkin lymphoma, a study published in the journal The Lancet Oncology has shown.1

For this international, open-label, phase 3 GADOLIN trial, investigators enrolled 396 adult patients with histologically documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab. Participants were randomly assigned 1:1 to receive obinutuzumab 1000 mg IV on days 1, 8, and 15 during cycle 1 and on day 1 during cycles 2 to 6 plus bendamustine 90 mg/m2 IV on days 1 and 2 during cycles 1 to 6, or bendamustine monotherapy 120 mg/m2 IV on days 1 and 2 for 6, 28-day cycles. Patients in the obinutuzumab group without disease progression after induction then received obinutuzumab maintenance at a dose of 1000 mg IV every 2 months for up to 2 years.

After a median follow-up time of 21.9 months in the obinutuzumab group and 20.3 months in the bendamustine monotherapy group, median progression-free survival had not yet been reached (95% CI, 22.5-not estimable) with obinutuzumab and bendamustine, compared with 14.9 months (95% CI, 12.8-16.6) with bendamustine monotherapy (hazard ratio, 0.55; 95% CI, 0.40-0.74; P = .0001).

Grade 3 to 5 adverse events were reported in 68% of immunotherapy-treated patients, versus 62% in those treated with single-agent bendamustine. Treatment-related adverse events led to death in 3 patients in the combination arm and 5 patients in the bendamustine monotherapy group.

RELATED: Patient-focused NCCN Guidelines for Non-Hodgkin Lymphoma Reflect Dramatic Changes in Treatment

The findings suggest that obinutuzumab plus bendamustine followed by obinutuzumab maintenance is a new treatment option for patients with indolent non-Hodgkin lymphoma who have relapsed after or are no longer responding to rituximab-based treatment.

Reference

  1. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial [published online ahead of print June 23, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)30097-3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs